Neuland Laboratories Announces Q4 FY26 Results: Total Income Hits Rs. 788.7 Crore
Hyderabad, India, May 12, 2026 - Neuland Laboratories Limited (NLL), a pharmaceutical manufacturer, announced its financial results for the year ended March 31, 2026. The company specializes in providing active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions services to customers in approximately 80 countries.Speaking on the performance, Neuland Laboratories Limited Chief Executive Officer and Managing Director, Mr. Saharsh Davuluri, stated that the company concluded FY26 on a strong note, aligning with original expectations. He highlighted the good business visibility in the short to medium term, which is anchored by commercial and near-commercial molecules.
Mr. Davuluri emphasized that the focus on execution discipline, customer satisfaction, and protection of business fundamentals is central to ensuring sustained growth. Furthermore, he noted that the company is laying groundwork for growth beyond the current horizon through investments in Peptide Manufacturing and the new R&D Centre, both of which are proceeding according to plan. The Business Development strategy is focused on attracting projects that support high quality, sustainable growth.
Financial Performance Summary
The financial results for the quarter and full year ending March 31, 2026, showed significant year-over-year growth. The performance figures are detailed below:| Particulars (Rs. crore) | Q4FY26 | Q4FY25 | YoY (%) | Q3FY26 | QoQ (%) |
|---|---|---|---|---|---|
| Total Income | 788.7 | 335.8 | 134.9% | 447.8 | 76.1% |
| EBITDA | 319.4 | 58.2 | 448.6% | 85.0 | 275.8% |
| EBITDA Margin | 40.5% | 17.3% | 2316 bps | 19.0% | 2151 bps |
| Profit Before Tax | 287.0 | 39.0 | 636.6% | 54.3 | 428.9% |
| PBT Margin | 36.4% | 11.6% | 2479 bps | 12.1% | 2430 bps |
| Profit After Tax | 212.5 | 27.7 | 666.3% | 40.4 | 425.8% |
Upcoming Earnings Call
The company is scheduled to hold a one-hour Earnings call on Tuesday, May 12, 2026, at 17:30 hrs IST. During the call, management will discuss the Company's performance and address questions from participants.About Neuland Laboratories Limited
For over four decades, Neuland Labs has maintained a leading position in the manufacturing of APIs through its cGMP manufacturing facilities. The company services customers in close to 80 countries and has developed over 300 processes and 100 APIs. Neuland Labs has also filed more than 1000 Regulatory filings across the US, the European Union, and other geographies. Its commitment to quality is evidenced by various cGMP certifications, including U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI 'SID & GP' Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001, and ISO 27001.NEULANDLAB Stock Price Movement
Neuland Laboratories Limited shares today shed ₹450.00, dropping 2.56% to settle at ₹17,003 in post-market trading. The stock saw significant activity, recording a total volume of 106,204 shares for the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.